Systematic Review and Meta-analysis of Pharmacological Treatment of the Symptoms of Attention-deficit/hyperactivity Disorder in Children with Pervasive Developmental Disorders

Overview

Journal J Autism Dev Disord

Publisher Springer

Date 2013 Mar 8

PMID 23468071

Citations 40

Authors

Brian Reichow

Fred R Volkmar

Michael H Bloch

Affiliations

Soon will be listed here.

Abstract

Many children with pervasive developmental disorders (PDD) exhibit behaviors and symptoms of attention-deficit/hyperactivity disorder (ADHD). We sought to determine the relative efficacy of medications for treating ADHD symptoms in children with PDD by identifying all double-blind, randomized, placebo-controlled trials examining the efficacy of medications for treating ADHD symptoms in children with PDD. We located seven trials involving 225 children. A random effects meta-analysis of four methylphenidate trials showed methylphenidate to be effective for treating ADHD symptoms in children with PDD (ES = .67). Several adverse events were greater for children were taking methylphenidate compared to placebo. An individual trial of clonidine and two trials of atomoxetine suggest these agents may also be effective in treating ADHD symptoms in children with PDD.

Citing Articles

The SASOP/PsychMg child and adolescent attention-deficit/hyperactivity disorder guidelines.

Belsham B, Kelly L, Schoeman R S Afr J Psychiatr. 2025; 31:2357.

PMID: 40061576 PMC: 11886469. DOI: 10.4102/sajpsychiatry.v31i0.2357.

Observing the behavioural effects of methylphenidate in children and adolescents with ASD-ADHD dual diagnosis: A mini review.

Dimitri D, Delia G, Arduino M, Turco N, Fioretto F Front Child Adolesc Psychiatry. 2025; 2():1052115.

PMID: 39816881 PMC: 11732115. DOI: 10.3389/frcha.2023.1052115.

Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms.

Manter M, Birtwell K, Bath J, Friedman N, Keary C, Neumeyer A BMC Med. 2025; 23(1):11.

PMID: 39773705 PMC: 11705908. DOI: 10.1186/s12916-024-03814-0.

Response inhibition as a critical executive function in differentiating attention-deficit/hyperactivity disorder from autism spectrum disorder: a comprehensive attention test study.

Lee K, Cho I, Park J, Choi H, Cheon K Front Psychiatry. 2024; 15:1426376.

PMID: 39564462 PMC: 11574416. DOI: 10.3389/fpsyt.2024.1426376.

Stimulant medication and symptom interrelations in children, adolescents and adults with attention-deficit/hyperactivity disorder.

van der Pal Z, Geurts H, Haslbeck J, van Keeken A, Bruijn A, Douw L Eur Child Adolesc Psychiatry. 2024; .

PMID: 39527154 DOI: 10.1007/s00787-024-02610-8.

References

Lecavalier L . Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. J Autism Dev Disord. 2006; 36(8):1101-14. DOI: 10.1007/s10803-006-0147-5. View

Rosenberg R, Mandell D, Farmer J, Law J, Marvin A, Law P . Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008. J Autism Dev Disord. 2009; 40(3):342-51. DOI: 10.1007/s10803-009-0878-1. View

Jaselskis C, Cook Jr E, Fletcher K, Leventhal B . Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol. 1992; 12(5):322-7. View

Connor D, Fletcher K, Swanson J . A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999; 38(12):1551-9. DOI: 10.1097/00004583-199912000-00017. View

Holtmann M, Bolte S, Poustka F . Attention deficit hyperactivity disorder symptoms in pervasive developmental disorders: association with autistic behavior domains and coexisting psychopathology. Psychopathology. 2007; 40(3):172-7. DOI: 10.1159/000100007. View

Harfterkamp M, van de Loo-Neus G, Minderaa R, van der Gaag R, Escobar R, Schacht A . A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2012; 51(7):733-41. DOI: 10.1016/j.jaac.2012.04.011. View

Leyfer O, Folstein S, Bacalman S, Davis N, Dinh E, Morgan J . Comorbid psychiatric disorders in children with autism: interview development and rates of disorders. J Autism Dev Disord. 2006; 36(7):849-61. DOI: 10.1007/s10803-006-0123-0. View

. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005; 62(11):1266-74. DOI: 10.1001/archpsyc.62.11.1266. View

Aman M, Eugene Arnold L, McDougle C, Vitiello B, Scahill L, Davies M . Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol. 2005; 15(6):869-84. DOI: 10.1089/cap.2005.15.869. View

10.

Spencer T, Biederman J, Wilens T, Harding M, ODonnell D, Griffin S . Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996; 35(4):409-32. DOI: 10.1097/00004583-199604000-00008. View

11.

Mandell D, Morales K, Marcus S, Stahmer A, Doshi J, Polsky D . Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics. 2008; 121(3):e441-8. PMC: 2861431. DOI: 10.1542/peds.2007-0984. View

12.

Stigler K, Desmond L, Posey D, Wiegand R, McDougle C . A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004; 14(1):49-56. DOI: 10.1089/104454604773840481. View

13.

Yerys B, Wallace G, Sokoloff J, Shook D, James J, Kenworthy L . Attention deficit/hyperactivity disorder symptoms moderate cognition and behavior in children with autism spectrum disorders. Autism Res. 2009; 2(6):322-33. PMC: 3012375. DOI: 10.1002/aur.103. View

14.

Sinzig J, Walter D, Doepfner M . Attention deficit/hyperactivity disorder in children and adolescents with autism spectrum disorder: symptom or syndrome?. J Atten Disord. 2009; 13(2):117-26. DOI: 10.1177/1087054708326261. View

15.

Oswald D, Sonenklar N . Medication use among children with autism spectrum disorders. J Child Adolesc Psychopharmacol. 2007; 17(3):348-55. DOI: 10.1089/cap.2006.17303. View

16.

Faraone S, Buitelaar J . Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2009; 19(4):353-64. DOI: 10.1007/s00787-009-0054-3. View

17.

Quintana H, Birmaher B, Stedge D, Lennon S, Freed J, Bridge J . Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord. 1995; 25(3):283-94. DOI: 10.1007/BF02179289. View

18.

Gargaro B, Rinehart N, Bradshaw J, Tonge B, Sheppard D . Autism and ADHD: how far have we come in the comorbidity debate?. Neurosci Biobehav Rev. 2010; 35(5):1081-8. DOI: 10.1016/j.neubiorev.2010.11.002. View

19.

Schachter H, Pham B, King J, Langford S, Moher D . How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2002; 165(11):1475-88. PMC: 81663. View

20.

van der Meer J, Oerlemans A, van Steijn D, Lappenschaar M, de Sonneville L, Buitelaar J . Are autism spectrum disorder and attention-deficit/hyperactivity disorder different manifestations of one overarching disorder? Cognitive and symptom evidence from a clinical and population-based sample. J Am Acad Child Adolesc Psychiatry. 2012; 51(11):1160-1172.e3. DOI: 10.1016/j.jaac.2012.08.024. View